NASDAQ:AKAO - Achaogen Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.77 -0.03 (-1.67 %) (As of 11/15/2018 04:00 PM ET)Previous Close$1.80Today's Range$1.76 - $1.8052-Week Range$1.70 - $15.00Volume544,000 shsAverage Volume1.11 million shsMarket Capitalization$92.24 millionP/E Ratio-0.56Dividend YieldN/ABeta0.67 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Achaogen, Inc., a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae; and therapeutic antibody discovery program. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited to manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California. Receive AKAO News and Ratings via Email Sign-up to receive the latest news and ratings for AKAO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AKAO Previous Symbol CUSIPN/A Webwww.achaogen.com Phone650-800-3636 Debt Debt-to-Equity Ratio1.00 Current Ratio2.54 Quick Ratio2.52 Price-To-Earnings Trailing P/E Ratio-0.56 Forward P/E Ratio-0.46 P/E GrowthN/A Sales & Book Value Annual Sales$11.18 million Price / Sales7.30 Cash FlowN/A Price / CashN/A Book Value$0.54 per share Price / Book3.28 Profitability EPS (Most Recent Fiscal Year)($3.17) Net Income$-125,610,000.00 Net Margins-2,045.86% Return on Equity-214.74% Return on Assets-106.90% Miscellaneous Employees230 Outstanding Shares46,120,000Market Cap$92.24 million OptionableOptionable Achaogen (NASDAQ:AKAO) Frequently Asked Questions What is Achaogen's stock symbol? Achaogen trades on the NASDAQ under the ticker symbol "AKAO." How were Achaogen's earnings last quarter? Achaogen Inc (NASDAQ:AKAO) announced its earnings results on Monday, August, 6th. The biopharmaceutical company reported ($1.11) EPS for the quarter, missing the Zacks' consensus estimate of ($0.92) by $0.19. The biopharmaceutical company earned $2.56 million during the quarter, compared to the consensus estimate of $1.49 million. Achaogen had a negative return on equity of 214.74% and a negative net margin of 2,045.86%. View Achaogen's Earnings History. When is Achaogen's next earnings date? Achaogen is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for Achaogen. What price target have analysts set for AKAO? 11 analysts have issued 12-month target prices for Achaogen's stock. Their predictions range from $3.00 to $22.00. On average, they anticipate Achaogen's share price to reach $10.8571 in the next twelve months. This suggests a possible upside of 513.4% from the stock's current price. View Analyst Price Targets for Achaogen. What is the consensus analysts' recommendation for Achaogen? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achaogen in the last year. There are currently 9 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Achaogen. What are Wall Street analysts saying about Achaogen stock? Here are some recent quotes from research analysts about Achaogen stock: 1. HC Wainwright analysts commented, "916-3963, POS Risk-adj value Full value Rating ZEMDRI – U.S. 100% $1.92 $1.92 Shares outstanding 46,120 2018 ZEMDRI – EU 35% $0.64 $1.83 Current share price $2.25 Discount rate 18.0% C-Scape – U.S." (11/12/2018) 2. Mizuho analysts commented, "We currently project a cash runway into mid-2019. In our valuation, we assume a $200 mil capital raise at $3.50/share in 1Q19 and we also increased our discount rate from 10% to 17% to reflect significantly increased risks. Our PT goes to $8." (11/6/2018) 3. According to Zacks Investment Research, "Achaogen, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae. Achaogen, Inc. is headquartered in South San Francisco, California. " (10/17/2018) Has Achaogen been receiving favorable news coverage? Media coverage about AKAO stock has trended positive this week, according to InfoTrie. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Achaogen earned a coverage optimism score of 3.0 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an effect on the company's share price in the near future. Are investors shorting Achaogen? Achaogen saw a drop in short interest during the month of October. As of October 15th, there was short interest totalling 8,481,348 shares, a drop of 13.6% from the September 28th total of 9,812,829 shares. Based on an average daily volume of 701,377 shares, the days-to-cover ratio is presently 12.1 days. Currently, 33.9% of the company's shares are short sold. View Achaogen's Current Options Chain. Who are some of Achaogen's key competitors? Some companies that are related to Achaogen include Cytokinetics (CYTK), Verrica Pharmaceuticals (VRCA), American Brivision (Holding) (ABVC), Savara (SVRA), ZIOPHARM Oncology (ZIOP), Minerva Neurosciences (NERV), Seres Therapeutics (MCRB), Kalvista Pharmaceuticals (KALV), resTORbio (TORC), TapImmune (MRKR), Adamas Pharmaceuticals (ADMS), Merus (MRUS), Aratana Therapeutics (PETX), Aclaris Therapeutics (ACRS) and Keryx Biopharmaceuticals (KERX). Who are Achaogen's key executives? Achaogen's management team includes the folowing people: Mr. Blake Wise, CEO & Director (Age 47)Dr. Kenneth J. Hillan, Pres, Director and Pres of R&D (Age 57)Mr. Gary Loeb, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 48)Ms. Zeryn Sarpangal, CFO & Principal Accounting Officer (Age 38)Ms. Elizabeth Bhatt, Chief Bus. Officer & COO (Age 50) Who are Achaogen's major shareholders? Achaogen's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Foresite Capital Management III LLC (5.15%), AXA (2.00%), Gabelli Funds LLC (0.68%), JPMorgan Chase & Co. (0.65%), JPMorgan Chase & Co. (0.64%) and Teton Advisors Inc. (0.57%). Company insiders that own Achaogen stock include Blake Wise, Equity Opportunities Iv Growth, Gary Loeb, Ian Friedland, Janet Dorling, Kenneth J Hillan, Robert W Duggan, Tobin Schilke and Zeryn Sarpangal. View Institutional Ownership Trends for Achaogen. Which major investors are selling Achaogen stock? AKAO stock was sold by a variety of institutional investors in the last quarter, including Foresite Capital Management III LLC, Renaissance Technologies LLC and Wells Fargo & Company MN. Company insiders that have sold Achaogen company stock in the last year include Blake Wise, Gary Loeb, Janet Dorling, Kenneth J Hillan and Tobin Schilke. View Insider Buying and Selling for Achaogen. Which major investors are buying Achaogen stock? AKAO stock was purchased by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., JPMorgan Chase & Co., AXA, SG Americas Securities LLC, Teton Advisors Inc., Gabelli Funds LLC, Point72 Asset Management L.P. and Gamco Investors INC. ET AL. Company insiders that have bought Achaogen stock in the last two years include Equity Opportunities Iv Growth and Robert W Duggan. View Insider Buying and Selling for Achaogen. How do I buy shares of Achaogen? Shares of AKAO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Achaogen's stock price today? One share of AKAO stock can currently be purchased for approximately $1.77. How big of a company is Achaogen? Achaogen has a market capitalization of $92.24 million and generates $11.18 million in revenue each year. The biopharmaceutical company earns $-125,610,000.00 in net income (profit) each year or ($3.17) on an earnings per share basis. Achaogen employs 230 workers across the globe. What is Achaogen's official website? The official website for Achaogen is http://www.achaogen.com. How can I contact Achaogen? Achaogen's mailing address is 1 TOWER PLACE SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-800-3636 or via email at [email protected] MarketBeat Community Rating for Achaogen (NASDAQ AKAO)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 324 (Vote Outperform)Underperform Votes: 231 (Vote Underperform)Total Votes: 555MarketBeat's community ratings are surveys of what our community members think about Achaogen and other stocks. Vote "Outperform" if you believe AKAO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKAO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/15/2018 by MarketBeat.com StaffFeatured Article: What is Compound Interest?